786 related articles for article (PubMed ID: 9840942)
41. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status.
Esteller M; Tortola S; Toyota M; Capella G; Peinado MA; Baylin SB; Herman JG
Cancer Res; 2000 Jan; 60(1):129-33. PubMed ID: 10646864
[TBL] [Abstract][Full Text] [Related]
42. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression.
Vonlanthen S; Heighway J; Altermatt HJ; Gugger M; Kappeler A; Borner MM; van Lohuizen M; Betticher DC
Br J Cancer; 2001 May; 84(10):1372-6. PubMed ID: 11355949
[TBL] [Abstract][Full Text] [Related]
43. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.
Sharpless NE; Bardeesy N; Lee KH; Carrasco D; Castrillon DH; Aguirre AJ; Wu EA; Horner JW; DePinho RA
Nature; 2001 Sep; 413(6851):86-91. PubMed ID: 11544531
[TBL] [Abstract][Full Text] [Related]
44. G1 control gene status is frequently altered in resectable non-small cell lung cancer.
Betticher DC; White GR; Vonlanthen S; Liu X; Kappeler A; Altermatt HJ; Thatcher N; Heighway J
Int J Cancer; 1997 Oct; 74(5):556-62. PubMed ID: 9355981
[TBL] [Abstract][Full Text] [Related]
45. Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers.
Pacifico A; Goldberg LH; Peris K; Chimenti S; Leone G; Ananthaswamy HN
Br J Dermatol; 2008 Feb; 158(2):291-7. PubMed ID: 18070208
[TBL] [Abstract][Full Text] [Related]
46. Reduced transcription of the RB2/p130 gene in human lung cancer.
Xue Jun H; Gemma A; Hosoya Y; Matsuda K; Nara M; Hosomi Y; Okano T; Kurimoto F; Seike M; Takenaka K; Yoshimura A; Toyota M; Kudoh S
Mol Carcinog; 2003 Nov; 38(3):124-9. PubMed ID: 14587097
[TBL] [Abstract][Full Text] [Related]
47. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
48. Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice.
Floyd HS; Jennings-Gee JE; Kock ND; Miller MS
Mol Carcinog; 2006 Jul; 45(7):506-17. PubMed ID: 16482519
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
Geradts J; Kratzke RA; Niehans GA; Lincoln CE
Cancer Res; 1995 Dec; 55(24):6006-11. PubMed ID: 8521382
[TBL] [Abstract][Full Text] [Related]
50. Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
Iolascon A; Della Ragione F; Giordani L; Serra A; Saglio G; Faienza MF
Haematologica; 1998 Sep; 83(9):771-7. PubMed ID: 9825572
[TBL] [Abstract][Full Text] [Related]
51. Rb and p16INK4a expression in resected non-small cell lung tumors.
Kratzke RA; Greatens TM; Rubins JB; Maddaus MA; Niewoehner DE; Niehans GA; Geradts J
Cancer Res; 1996 Aug; 56(15):3415-20. PubMed ID: 8758904
[TBL] [Abstract][Full Text] [Related]
52. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
53. Promoter methylations of p16INK4a and p14ARF genes in early and advanced gastric cancer. Correlations of the modes of their occurrence with histologic type.
Tsujimoto H; Hagiwara A; Sugihara H; Hattori T; Yamagishi H
Pathol Res Pract; 2002; 198(12):785-94. PubMed ID: 12608655
[TBL] [Abstract][Full Text] [Related]
54. Downregulation and aberrant promoter methylation of p16INK4A: a possible novel heritable susceptibility marker to retinoblastoma.
Indovina P; Acquaviva A; De Falco G; Rizzo V; Onnis A; Luzzi A; Giorgi F; Hadjistilianou T; Toti P; Tomei V; Pentimalli F; Carugi A; Giordano A
J Cell Physiol; 2010 Apr; 223(1):143-50. PubMed ID: 20039270
[TBL] [Abstract][Full Text] [Related]
55. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Fujishita T; Mizushima Y; Kashii T; Kobayashi M
Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
[TBL] [Abstract][Full Text] [Related]
56. Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer.
Wang J; Walsh G; Liu DD; Lee JJ; Mao L
Cancer Res; 2006 Sep; 66(17):8361-6. PubMed ID: 16951144
[TBL] [Abstract][Full Text] [Related]
57. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation.
Marchetti A; Doglioni C; Barbareschi M; Buttitta F; Pellegrini S; Bertacca G; Chella A; Merlo G; Angeletti CA; Dalla Palma P; Bevilacqua G
Oncogene; 1996 Mar; 12(6):1319-24. PubMed ID: 8649834
[TBL] [Abstract][Full Text] [Related]
58. [Alternative protein p19ARF: a genuine tumor suppressor gene].
Larsen CJ
Bull Cancer; 1998 Apr; 85(4):304-6. PubMed ID: 9752293
[TBL] [Abstract][Full Text] [Related]
59. Critical role of deltaDNMT3B4/2 in regulating RASSF1A promoter-specific DNA methylation in non-small cell lung cancer.
Wang SH; Liu NH; Wang J; Bai H; Mao L
Chin Med J (Engl); 2008 Sep; 121(17):1712-21. PubMed ID: 19024105
[TBL] [Abstract][Full Text] [Related]
60. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.
Shapiro GI; Edwards CD; Kobzik L; Godleski J; Richards W; Sugarbaker DJ; Rollins BJ
Cancer Res; 1995 Feb; 55(3):505-9. PubMed ID: 7834618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
